Â
Â
Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona.
These data will highlight exciting findings that have emerged over the past year, including:
·      Updated clinical results for ONC201 in pediatric and adult H3 K27M-mutant gliomas
·      Extension of ONC201 activity to other brain tumors
·      Synergy antitumor activity of ONC201 in combination with other treatments
·      Activity of ONC206 in medulloblastoma
·      IND-enabling studies with ONC206
·      Distinctions in the activity of ONC201 and ONC206
·      Inhibition of mitochondrial function by ONC201
·      The capability of the imipridone family to bind to distinct molecular targets
Oncoceutics and academic investigators will present a range of results with imipridones that will include mechanistic and efficacy findings from preclinical models that detail their unique therapeutic potential in neuro-oncology. In addition, updated safety, pharmacokinetic, pharmacodynamic, and efficacy results from clinical trials with ONC201 in high-grade glioma patients will be reported. These results are largely derived from the ongoing clinical program that is dedicated to exploring ONC201 a molecularly-defined patient population (H3 K27M-mutant glioma). The rationale for the upcoming first-in-human clinical trial of ONC206 in adult recurrent CNS tumors will also be highlighted.
Summaries and presentation information are provided below:
|
Date/Time |
Location |
Abstract Title |
Presenter |
|
Wednesday 11/20 |
 |
 |
 |
|
9:40 – 9:50 PM |
JW Marriott |
Selective targeting of dopamine receptor dysregulation in high grade gliomas with ONC201 |
Varun Prabhu, PhD, Oncoceutics |
|
Thursday    11/21 |
 |
 |
 |
|
 5:00 – 7:00 PM |
 |
 Investigator Meeting |
 |
|
Friday 11/22 |
 |
 |
 |
|
 7:30 – 9:30 PM |
Ballroom Lawn |
Imipridone Structure Activity Relationship Uncovers ONC206 as the Next Bitopic DRD2 Antagonist for                                                       Oncology with Differentiated Receptor Pharmacology                                                      |
Varun Prabhu, PhD, Oncoceutics |
|
 7:30 – 9:30 PM |
Ballroom Lawn |
Single agent ONC201 in previously treated, progressive adult H3 K27M-mutant glioma |
Isabel Arrillaga- Romany, MD, PhD, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â MGHÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â |
|
7:30 – 9:30 PM |
Ballroom Lawn |
Role of ONC206 in regulating medulloblastoma tumor progression |
Anshu Malhotra, PhD, Emory University |
|
7:38 – 7:42 PM |
Wildflower B |
Receptor pharmacology of ONC201: The first bitopic DRD2 antagonist for clinical neuro-oncology |
Josh Allen, PhD, Oncoceutics |
Â
|
Saturday 11/23 |
 |
 |
 |
|
 7:15 – 8:30 AM |
Grand Canyon 8-13 |
H3K27M glioma and ONC201 (SNO-EANO Joint session) |
Isabel Arrillaga- Romany, MD, PhD, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â MGHÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â |
|
3:45 – 3:55 PM |
Grand Canyon 1-6 |
Clinical efficacy of ONC201 in thalamic H3 K27M- mutant glioma |
Carl Koschmann, MD, Michigan Medicine |
|
4:40 – 4:45 PM |
Grand Canyon 1-6 |
Phase I clinical trial of ONC201 in pediatric H3 K27M- mutant glioma or newly diagnosed DIPG |
Sharon Gardner, MD, NYU Langone Health |
|
 5:00 – 7:00 PM |
 Ballroom Lawn |
Preclinical combination of ONC201 with radiotherapy or Temozolomide in GBM, DIPG and ATRT cell lines results in dopamine receptor antagonism, ATF4                                                       induction and cell death                                                      |
Lanlan Zhou, MD, PhD, Brown University |
|
5:00 – 7:00 PM |
Ballroom Lawn |
Metabolic rewiring by ONC201/TIC10 and 2- Deoxyglucose has synergistic anti-glioblastoma activity |
Josh Allen, PhD, Oncoceutics |
|
5:00 – 7:00 PM |
Ballroom Lawn |
PDTM-25 Study of ONC201 in pre-clinical models of DIPG |
Wafik Zaky, MD, MD Anderson |
|
5:00 – 7:00 PM |
Ballroom Lawn |
IND-enabling Characterization of ONC206 as the Next Bitopic DRD2 antagonist for Neuro-oncology |
Varun Prabhu, PhD, Oncoceutics |
 About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “imipridones,†that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist, the first one that exhibits a highly specific bi-topic binding to the receptor. The company is supported by grants from the NCI, FDA, The Musella Foundation, and a series of private and public partnerships.
Â
  Visit Oncoceutics  for more information.
Â